Related Experiment Video

Updated: Nov 26, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K

ALKBH2 inhibition alleviates malignancy in colorectal cancer by regulating BMI1-mediated activation of NF-κB pathway

Bingxin Ke1, Kejun Ye2, Shaobing Cheng2

  • 1Department of Colorectal Surgery, the First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79, Qingchun Road, Xiacheng District, Hangzhou City, 310003, Zhejiang Province, China. 1514012@zju.edu.cn.

World Journal of Surgical Oncology
|December 11, 2020
PubMed
Abstract

Insights

AlkBH2 gene suppression reduces colorectal cancer (CRC) malignancy by inhibiting BMI1 and NF-κB pathway activation. This finding highlights AlkBH2 as a potential therapeutic target for CRC treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The alkB homolog 2 (ALKBH2) gene, implicated in DNA repair, is expressed in various cancers, but its role in colorectal carcinoma (CRC) is not well understood.
  • Understanding ALKBH2's function in CRC is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the mechanism and function of ALKBH2 in colorectal carcinoma.
  • To explore the potential of ALKBH2 as a therapeutic target for CRC.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) to measure ALKBH2 expression in CRC tissues and cells.
  • Cell Counting Kit-8 (CCK-8), transwell assays, and Western blotting to assess proliferation, invasion, and epithelial-mesenchymal transition (EMT).
  • Western blotting and luciferase reporter assays to determine the effect of ALKBH2 on the BMI1 and NF-κB pathway.

Main Results:

  • ALKBH2 expression was significantly upregulated in CRC tissues and cells.
  • ALKBH2 knockdown suppressed CRC cell proliferation, invasion, and EMT, increasing E-cadherin and decreasing N-cadherin expression.
  • Silencing ALKBH2 inhibited BMI1 expression, reduced NF-κB p65 nuclear accumulation, and decreased NF-κB activity. BMI1 upregulation reversed the effects of ALKBH2 knockdown.

Conclusions:

  • ALKBH2 suppression alleviates CRC malignancy by regulating the BMI1-mediated activation of the NF-κB pathway.
  • ALKBH2 presents a potential therapeutic target for human colorectal carcinoma.
Keywords:
Alpha-ketoglutarate dependent dioxygenaseB cell-specific Moloney murine leukemia virus integration site 1Colorectal carcinomaNF-κB pathwayalkB homolog 2

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.9K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.1K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
8.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K